ReviewFrontiers in pharmacology2026
The effect of lidocaine in breast cancer: a concise overview of preclinical and clinical evidence.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative recurrence, distant metastasis, and chemotherapy resistance in breast cancer present significant challenges in clinical treatment. Improving perioperative intervention strategies is crucial for enhancing patient prognosis. Lidocaine, a commonly used local anesthetic, has recently been shown to possess potential anti-breast cancer effects, offering a novel therapeutic direction through its drug repurposing potential. This review explores the multifaceted mechanisms by which lidocaine exerts anti-cancer effects, including nuclear regulation, membrane receptor channel inhibition, tumor microenvironment reprogramming, autophagy activation, and synergistic effects when combined with chemotherapy agents. Furthermore, the review discusses the limitations of current research, incorporating clinical evidence. This article provides a theoretical foundation for the perioperative application of lidocaine in breast cancer and the development of combination therapies, while also outlining future research directions to promote the clinical translation of "old drugs, new uses."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.